"In the DIG trial, published in 1997, digoxin had a neutral effect on the primary endpoint of mortality, but a 28% reduction in heart failure hospitalizations (a secondary endpoint) was observed.
Wearable device data could predict New York Heart Association functional class similarly to clinical measures and six-minute walk test. HealthDay News — For patients with atrial fibrillation, digoxin ...
27don MSN
AIIMS-led trial finds low-cost drug digoxin may improve outcomes in rheumatic heart disease
A trial by AIIMS shows digoxin may reduce worsening heart failure in rheumatic heart disease patients, offering a low-cost treatment option.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results